Summary
Global Markets Direct’s, ‘Hodgkin Lymphoma - Pipeline Review, H1 2016’, provides an overview of the Hodgkin Lymphoma pipeline landscape.
The report provides comprehensive information on the therapeutics under development for Hodgkin Lymphoma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Hodgkin Lymphoma and features dormant and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.
Scope
- The report provides a snapshot of the global therapeutic landscape of Hodgkin Lymphoma
- The report reviews pipeline therapeutics for Hodgkin Lymphoma by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Hodgkin Lymphoma therapeutics and enlists all their major and minor projects
- The report assesses Hodgkin Lymphoma therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Hodgkin Lymphoma
Reasons to buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Hodgkin Lymphoma
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Hodgkin Lymphoma pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Companies Mentioned
4SC AG
Acetylon Pharmaceuticals, Inc.
Actinium Pharmaceuticals, Inc.
ADC Therapeutics Sarl
Affimed Therapeutics AG
Arbutus Biopharma Corporation
Bellicum Pharmaceuticals, Inc.
Bristol-Myers Squibb Company
Celgene Corporation
Cell Medica Limited
Cellular Biomedicine Group, Inc.
Constellation Pharmaceuticals, Inc.
Curis, Inc.
Faron Pharmaceuticals Oy
Fate Therapeutics, Inc.
Gamida Cell Ltd.
Gilead Sciences, Inc.
Incyte Corporation
Merck & Co., Inc.
Mirati Therapeutics Inc.
Molecular Templates Inc.
NantKwest, Inc.
Novartis AG
Ono Pharmaceutical Co., Ltd.
Pfizer Inc.
Pharmacyclics, Inc.
Philogen S.p.A.
Rich Pharmaceuticals, Inc.
Seattle Genetics, Inc.
Selvita S.A.
Sigma-Tau S.p.A.
Spectrum Pharmaceuticals, Inc.
Stemline Therapeutics, Inc.
Syndax Pharmaceuticals, Inc.
Takeda Pharmaceutical Company Limited
TG Therapeutics, Inc.
Theravectys SA
Trillium Therapeutics Inc.
'
Table of Contents
Table of Contents 2
List of Tables 6
List of Figures 7
Introduction 8
Global Markets Direct Report Coverage 8
Hodgkin Lymphoma Overview 9
Therapeutics Development 10
Pipeline Products for Hodgkin Lymphoma - Overview 10
Pipeline Products for Hodgkin Lymphoma - Comparative Analysis 11
Hodgkin Lymphoma - Therapeutics under Development by Companies 12
Hodgkin Lymphoma - Therapeutics under Investigation by Universities/Institutes 16
Hodgkin Lymphoma - Pipeline Products Glance 17
Late Stage Products 17
Clinical Stage Products 18
Early Stage Products 19
Hodgkin Lymphoma - Products under Development by Companies 20
Hodgkin Lymphoma - Products under Investigation by Universities/Institutes 24
Hodgkin Lymphoma - Companies Involved in Therapeutics Development 25
4SC AG 25
Acetylon Pharmaceuticals, Inc. 26
Actinium Pharmaceuticals, Inc. 27
ADC Therapeutics Sarl 28
Affimed Therapeutics AG 29
Arbutus Biopharma Corporation 30
Bellicum Pharmaceuticals, Inc. 31
Bristol-Myers Squibb Company 32
Celgene Corporation 33
Cell Medica Limited 34
Cellular Biomedicine Group, Inc. 35
Constellation Pharmaceuticals, Inc. 36
Curis, Inc. 37
Faron Pharmaceuticals Oy 38
Fate Therapeutics, Inc. 39
Gamida Cell Ltd. 40
Gilead Sciences, Inc. 41
Incyte Corporation 42
Merck & Co., Inc. 43
Mirati Therapeutics Inc. 44
Molecular Templates Inc. 45
NantKwest, Inc. 46
Novartis AG 47
Ono Pharmaceutical Co., Ltd. 48
Pfizer Inc. 49
Pharmacyclics, Inc. 50
Philogen S.p.A. 51
Rich Pharmaceuticals, Inc. 52
Seattle Genetics, Inc. 53
Selvita S.A. 54
Sigma-Tau S.p.A. 55
Spectrum Pharmaceuticals, Inc. 56
Stemline Therapeutics, Inc. 57
Syndax Pharmaceuticals, Inc. 58
Takeda Pharmaceutical Company Limited 59
TG Therapeutics, Inc. 60
Theravectys SA 61
Trillium Therapeutics Inc. 62
Hodgkin Lymphoma - Therapeutics Assessment 63
Assessment by Monotherapy Products 63
Assessment by Combination Products 64
Assessment by Target 65
Assessment by Mechanism of Action 70
Assessment by Route of Administration 74
Assessment by Molecule Type 76
Drug Profiles 78
(INCB-039110 + INCB-040093) - Drug Profile 78
abexinostat hydrochloride - Drug Profile 79
acalisib - Drug Profile 82
ADCT-301 - Drug Profile 83
AFM-13 - Drug Profile 84
Alocrest - Drug Profile 85
aNK Program - Drug Profile 87
azacitidine - Drug Profile 90
BMS-986016 - Drug Profile 94
BPX-501 - Drug Profile 95
brentuximab vedotin - Drug Profile 97
CBM-C30.1 - Drug Profile 104
Cellular Immunotherapy for Hodgkin Lymphoma and Non-Hodgkin Lymphoma - Drug Profile 105
Cellular Immunotherapy for Oncology - Drug Profile 106
Cellular Immunotherapy to Target CD30 for Hodgkin and Non-Hodgkin Lymphomas - Drug Profile 107
Cellular Immunotherapy to Target GM-CSF for Hodgkin Lymphoma and Chronic Lymphocytic Leukemia - Drug Profile 108
Cellular Immunotherapy to Target LMP, BARF-1 and EBNA1 for EBV Associated Cancers and Infection - Drug Profile 109
Cellular Immunotherapy to Target LMP-1 and LMP-2 for Oncology and Infectious Diseases - Drug Profile 110
Cellular Immunotherapy to Target NY-ESO-1, MAGEA4, PRAME, Survivin and Synovial Sarcoma X for Oncology - Drug Profile 111
CMD-003 - Drug Profile 112
CPI-0610 - Drug Profile 114
CUDC-907 - Drug Profile 115
entinostat - Drug Profile 117
Epstein-Barr virus vaccine - Drug Profile 121
Ferritarg - Drug Profile 122
FP-1304 - Drug Profile 123
FT-1050 - Drug Profile 124
haNK Program - Drug Profile 127
INCB-40093 - Drug Profile 129
Indimitecan - Drug Profile 130
Indotecan hydrochloride - Drug Profile 131
Iomab-B - Drug Profile 133
ipilimumab - Drug Profile 135
ixazomib citrate - Drug Profile 140
lirilumab - Drug Profile 144
MK-2206 - Drug Profile 146
mocetinostat - Drug Profile 149
Monoclonal Antibodies to Inhibit PD-1/PD-L1 for Hematological Malignancies - Drug Profile 152
Monoclonal Antibody Conjugate to Target CD45 for Oncology - Drug Profile 153
NiCord - Drug Profile 154
nivolumab - Drug Profile 155
NSC-678515 - Drug Profile 163
panobinostat - Drug Profile 164
pembrolizumab - Drug Profile 171
PF-06801591 - Drug Profile 181
PNK-007 - Drug Profile 182
procarbazine hydrochloride - Drug Profile 183
radretumab - Drug Profile 184
Recombinant Proteins for Melanoma and Hodgkin's Lymphoma - Drug Profile 186
resminostat - Drug Profile 187
ricolinostat - Drug Profile 193
RP-323 - Drug Profile 196
ruxolitinib phosphate - Drug Profile 197
SEL-24B489 - Drug Profile 202
SL-101 - Drug Profile 204
SL-501 - Drug Profile 205
temsirolimus - Drug Profile 206
TGR-1202 - Drug Profile 208
TKM-PLK1 - Drug Profile 211
TTI-621 - Drug Profile 213
Vaccine for Nasopharyngeal Cancer and Hodgkin Lymphoma - Drug Profile 215
Hodgkin Lymphoma - Recent Pipeline Updates 216
Hodgkin Lymphoma - Dormant Projects 339
Hodgkin Lymphoma - Discontinued Products 342
Hodgkin Lymphoma - Product Development Milestones 343
Featured News & Press Releases 343
Appendix 356
Methodology 356
Coverage 356
Secondary Research 356
Primary Research 356
Expert Panel Validation 356
Contact Us 356
Disclaimer 357
List of Tables
Number of Products under Development for Hodgkin Lymphoma, H1 2016 14
Number of Products under Development for Hodgkin Lymphoma - Comparative Analysis, H1 2016 15
Number of Products under Development by Companies, H1 2016 17
Number of Products under Development by Companies, H1 2016 (Contd..1) 18
Number of Products under Development by Companies, H1 2016 (Contd..2) 19
Number of Products under Investigation by Universities/Institutes, H1 2016 20
Comparative Analysis by Late Stage Development, H1 2016 21
Comparative Analysis by Clinical Stage Development, H1 2016 22
Comparative Analysis by Early Stage Development, H1 2016 23
Products under Development by Companies, H1 2016 24
Products under Development by Companies, H1 2016 (Contd..1) 25
Products under Development by Companies, H1 2016 (Contd..2) 26
Products under Development by Companies, H1 2016 (Contd..3) 27
Products under Investigation by Universities/Institutes, H1 2016 28
Hodgkin Lymphoma - Pipeline by 4SC AG, H1 2016 29
Hodgkin Lymphoma - Pipeline by Acetylon Pharmaceuticals, Inc., H1 2016 30
Hodgkin Lymphoma - Pipeline by Actinium Pharmaceuticals, Inc., H1 2016 31
Hodgkin Lymphoma - Pipeline by ADC Therapeutics Sarl, H1 2016 32
Hodgkin Lymphoma - Pipeline by Affimed Therapeutics AG, H1 2016 33
Hodgkin Lymphoma - Pipeline by Arbutus Biopharma Corporation, H1 2016 34
Hodgkin Lymphoma - Pipeline by Bellicum Pharmaceuticals, Inc., H1 2016 35
Hodgkin Lymphoma - Pipeline by Bristol-Myers Squibb Company, H1 2016 36
Hodgkin Lymphoma - Pipeline by Celgene Corporation, H1 2016 37
Hodgkin Lymphoma - Pipeline by Cell Medica Limited, H1 2016 38
Hodgkin Lymphoma - Pipeline by Cellular Biomedicine Group, Inc., H1 2016 39
Hodgkin Lymphoma - Pipeline by Constellation Pharmaceuticals, Inc., H1 2016 40
Hodgkin Lymphoma - Pipeline by Curis, Inc., H1 2016 41
Hodgkin Lymphoma - Pipeline by Faron Pharmaceuticals Oy, H1 2016 42
Hodgkin Lymphoma - Pipeline by Fate Therapeutics, Inc., H1 2016 43
Hodgkin Lymphoma - Pipeline by Gamida Cell Ltd., H1 2016 44
Hodgkin Lymphoma - Pipeline by Gilead Sciences, Inc., H1 2016 45
Hodgkin Lymphoma - Pipeline by Incyte Corporation, H1 2016 46
Hodgkin Lymphoma - Pipeline by Merck & Co., Inc., H1 2016 47
Hodgkin Lymphoma - Pipeline by Mirati Therapeutics Inc., H1 2016 48
Hodgkin Lymphoma - Pipeline by Molecular Templates Inc., H1 2016 49
Hodgkin Lymphoma - Pipeline by NantKwest, Inc., H1 2016 50
Hodgkin Lymphoma - Pipeline by Novartis AG, H1 2016 51
Hodgkin Lymphoma - Pipeline by Ono Pharmaceutical Co., Ltd., H1 2016 52
Hodgkin Lymphoma - Pipeline by Pfizer Inc., H1 2016 53
Hodgkin Lymphoma - Pipeline by Pharmacyclics, Inc., H1 2016 54
Hodgkin Lymphoma - Pipeline by Philogen S.p.A., H1 2016 55
Hodgkin Lymphoma - Pipeline by Rich Pharmaceuticals, Inc., H1 2016 56
Hodgkin Lymphoma - Pipeline by Seattle Genetics, Inc., H1 2016 57
Hodgkin Lymphoma - Pipeline by Selvita S.A., H1 2016 58
Hodgkin Lymphoma - Pipeline by Sigma-Tau S.p.A., H1 2016 59
Hodgkin Lymphoma - Pipeline by Spectrum Pharmaceuticals, Inc., H1 2016 60
Hodgkin Lymphoma - Pipeline by Stemline Therapeutics, Inc., H1 2016 61
Hodgkin Lymphoma - Pipeline by Syndax Pharmaceuticals, Inc., H1 2016 62
Hodgkin Lymphoma - Pipeline by Takeda Pharmaceutical Company Limited, H1 2016 63
Hodgkin Lymphoma - Pipeline by TG Therapeutics, Inc., H1 2016 64
Hodgkin Lymphoma - Pipeline by Theravectys SA, H1 2016 65
Hodgkin Lymphoma - Pipeline by Trillium Therapeutics Inc., H1 2016 66
Assessment by Monotherapy Products, H1 2016 67
Assessment by Combination Products, H1 2016 68
Number of Products by Stage and Target, H1 2016 70
Number of Products by Stage and Mechanism of Action, H1 2016 75
Number of Products by Stage and Route of Administration, H1 2016 79
Number of Products by Stage and Molecule Type, H1 2016 81
Hodgkin Lymphoma Therapeutics - Recent Pipeline Updates, H1 2016 220
Hodgkin Lymphoma - Dormant Projects, H1 2016 343
Hodgkin Lymphoma - Dormant Projects (Contd..1), H1 2016 344
Hodgkin Lymphoma - Dormant Projects (Contd..2), H1 2016 345
Hodgkin Lymphoma - Discontinued Products, H1 2016 346
List of Figures
Number of Products under Development for Hodgkin Lymphoma, H1 2016 14
Number of Products under Development for Hodgkin Lymphoma - Comparative Analysis, H1 2016 15
Number of Products under Development by Companies, H1 2016 16
Number of Products under Investigation by Universities/Institutes, H1 2016 20
Comparative Analysis by Late Stage Development, H1 2016 21
Comparative Analysis by Clinical Stage Development, H1 2016 22
Comparative Analysis by Early Stage Products, H1 2016 23
Assessment by Monotherapy Products, H1 2016 67
Number of Products by Top 10 Targets, H1 2016 69
Number of Products by Stage and Top 10 Targets, H1 2016 69
Number of Products by Top 10 Mechanism of Actions, H1 2016 74
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2016 74
Number of Products by Routes of Administration, H1 2016 78
Number of Products by Stage and Routes of Administration, H1 2016 78
Number of Products by Top 10 Molecule Types, H1 2016 80
Number of Products by Stage and Top 10 Molecule Types, H1 2016 80
